| A Study Collecting Remote Data in People With an Overweight Condition or Obesity on a Weight Management Program (NCT06805539) | Novo Nordisk A/S | 2025-04-14 |
| CAPTIVATE India - A Study to Assess the Prevalence of Cardiovascular Disease (CVD) in Individuals With Type 2 Diabetes Mellitus (T2DM) in India (NCT07121114) | Novo Nordisk A/S | 2025-04-09 |
| Prevalence of Weight Related Complications Across Diverse Weight Classifications - A Large Study in India, Pakistan, Philippines and Vietnam (NCT06843473) | Novo Nordisk A/S | 2025-03-18 |
| Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases (NCT06891365) | Novo Nordisk A/S | 2025-03-12 |
| A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease (NCT06612268) | Novo Nordisk A/S | 2025-02-17 |
| A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity (NCT06780449) | Novo Nordisk A/S | 2025-02-10 |
| A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants After 10 Days of Oral Dosing (NCT06820476) | Novo Nordisk A/S | 2025-02-09 |
| A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants (NCT06813924) | Novo Nordisk A/S | 2025-02-06 |
| Defeat Rare Disease in Asia and Pacific (APAC) DRDA - Haemophilia (NCT07163260) | Novo Nordisk A/S | 2025-01-31 |
| A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy (NCT06797869) | Novo Nordisk A/S | 2025-01-29 |
| A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin Pump (NCT06809621) | Novo Nordisk A/S | 2025-01-29 |
| A Real-world Assessment in Implementation of the MASH Patient Care Pathway in Chinese Population Using the Meinian Health Check-up Database (NCT06741111) | Novo Nordisk A/S | 2025-01-21 |
| A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia (NCT06609226) | Novo Nordisk A/S | 2025-01-10 |
| A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity (NCT06737536) | Novo Nordisk A/S | 2024-12-18 |
| A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters (NCT06709040) | Novo Nordisk A/S | 2024-12-13 |
| Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World (NCT06874751) | Novo Nordisk A/S | 2024-12-06 |
| A Study on How NNC0174-1213 Works in People With Overweight or Obesity. (NCT06719011) | Novo Nordisk A/S | 2024-12-03 |
| SPRING - Assess the Clinical Care Pathway of Population With T2D and CKD in Four European Countries Using Real-world Data (NCT06769646) | Novo Nordisk A/S | 2024-12-02 |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease (NCT06717698) | Novo Nordisk A/S | 2024-12-02 |
| A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity (NCT06716307) | Novo Nordisk A/S | 2024-12-02 |
| Levels of Inflammation in Middle East People With Cardiovascular Disease With/Without Kidney Disease (NCT06655493) | Novo Nordisk A/S | 2024-11-22 |
| A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or Obesity (NCT06718998) | Novo Nordisk A/S | 2024-11-20 |
| A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea (NCT07018544) | Novo Nordisk A/S | 2024-11-19 |
| A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia (NCT06859073) | Novo Nordisk A/S | 2024-11-13 |
| A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes (NCT06685185) | Novo Nordisk A/S | 2024-11-12 |
| Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients (NCT06574984) | Novo Nordisk A/S | 2024-11-10 |
| A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 Diabetes (NCT06113341) | Novo Nordisk A/S | 2024-11-07 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both (NCT06534411) | Novo Nordisk A/S | 2024-11-05 |
| A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV (NCT06642584) | Novo Nordisk A/S | 2024-10-15 |
| A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine (NCT06642571) | Novo Nordisk A/S | 2024-10-15 |
| A Research Study on the Effects of NNC0537-1482 in Healthy Individuals When Injected Under the Skin (NCT06625307) | Novo Nordisk A/S | 2024-10-03 |
| SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary (NCT06269120) | Novo Nordisk A/S | 2024-09-30 |
| A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy Men (NCT06649630) | Novo Nordisk A/S | 2024-09-23 |
| STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss (NCT06571383) | Novo Nordisk A/S | 2024-09-17 |
| Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents (NCT06588504) | Novo Nordisk A/S | 2024-09-10 |
| A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Patients With ASCVD and CKD in China Among Cardiologists and Nephrologists (NCT06589791) | Novo Nordisk A/S | 2024-09-09 |
| Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes (NCT06507475) | Novo Nordisk A/S | 2024-09-07 |
| A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity (NCT06577766) | Novo Nordisk A/S | 2024-09-03 |
| A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants (NCT06581627) | Novo Nordisk A/S | 2024-08-26 |
| A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function (NCT06559527) | Novo Nordisk A/S | 2024-08-20 |
| A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men (NCT06542536) | Novo Nordisk A/S | 2024-08-09 |
| Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors (NCT06285071) | Novo Nordisk A/S | 2024-08-08 |
| A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes (NCT06567041) | Novo Nordisk A/S | 2024-08-07 |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes (NCT06542874) | Novo Nordisk A/S | 2024-08-07 |
| A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause (NCT06513104) | Novo Nordisk A/S | 2024-07-18 |
| Insulin Initiation and Adherence Behaviours: a Cross Sectional Survey of Indian HCPs & Patients With Type 2 Diabetes (NCT06517784) | Novo Nordisk A/S | 2024-07-05 |
| A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or Obesity (NCT06478563) | Novo Nordisk A/S | 2024-06-27 |
| A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment (NCT06478550) | Novo Nordisk A/S | 2024-06-26 |
| ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack (NCT06118281) | Novo Nordisk A/S | 2024-06-25 |
| A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight (NCT06388187) | Novo Nordisk A/S | 2024-06-24 |
| A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant (NCT06461039) | Novo Nordisk A/S | 2024-06-14 |
| Special Use - Results Surveillance on Long-term Use With Wegovy® (NCT06283667) | Novo Nordisk A/S | 2024-06-11 |
| A Research Study of the Effect of Food on Etavopivat in Healthy Participants (NCT06433661) | Novo Nordisk A/S | 2024-05-28 |
| Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease (NCT06409130) | Novo Nordisk A/S | 2024-05-20 |
| A Research Study on Etavopivat in Participants With and Without Liver Disease (NCT06336018) | Novo Nordisk A/S | 2024-05-20 |
| Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes (NCT06403761) | Novo Nordisk A/S | 2024-05-06 |
| Remote Study Collecting Blood Glucose Values and Activity Data in Patients With Type 2 Diabetes on Different Treatments (NCT04809311) | Novo Nordisk A/S | 2024-04-30 |
| A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature (NCT05894876) | Novo Nordisk A/S | 2024-04-29 |
| A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes (NCT06340854) | Novo Nordisk A/S | 2024-04-19 |
| A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function (NCT06370819) | Novo Nordisk A/S | 2024-04-15 |
| Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan. (NCT06283641) | Novo Nordisk A/S | 2024-04-08 |
| A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation (NCT06200207) | Novo Nordisk A/S | 2024-04-01 |
| A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo (NCT06131372) | Novo Nordisk A/S | 2024-04-01 |
| A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People (NCT06336005) | Novo Nordisk A/S | 2024-03-28 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin (NCT06323161) | Novo Nordisk A/S | 2024-03-26 |
| A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists (NCT06322641) | Novo Nordisk A/S | 2024-03-26 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise (NCT06323174) | Novo Nordisk A/S | 2024-03-19 |
| A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight (NCT06326060) | Novo Nordisk A/S | 2024-03-18 |
| A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes (NCT06326047) | Novo Nordisk A/S | 2024-03-18 |
| Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease (NCT05725902) | Novo Nordisk A/S | 2024-03-09 |
| A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People (NCT06291285) | Novo Nordisk A/S | 2024-02-27 |
| A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight (NCT06289504) | Novo Nordisk A/S | 2024-02-27 |
| A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting (NCT06288412) | Novo Nordisk A/S | 2024-02-26 |
| A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight (NCT06207877) | Novo Nordisk A/S | 2024-02-23 |
| A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis (NCT06260709) | Novo Nordisk A/S | 2024-02-20 |
| A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4) (NCT06269107) | Novo Nordisk A/S | 2024-02-15 |
| A Study of How CagriSema Works on Appetite in People With Excess Body Weight (NCT06267092) | Novo Nordisk A/S | 2024-02-15 |
| A Research Study of a New Medicine (NNC0650-0013) in Healthy Men (NCT06284798) | Novo Nordisk A/S | 2024-01-29 |
| Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes (NCT06083675) | Novo Nordisk A/S | 2024-01-26 |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (NCT06221969) | Novo Nordisk A/S | 2024-01-16 |
| Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR) (NCT06351748) | Novo Nordisk A/S | 2024-01-02 |
| Prevalence and Economic Burden of Obesity-related Comorbidities in the Gulf Region: A Retrospective, Observational Study (NCT06288399) | Novo Nordisk A/S | 2023-12-21 |
| A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children. (NCT06188026) | Novo Nordisk A/S | 2023-12-18 |
| A Research Study in Saudi Arabia to Understand How the Dose Check App Used With Tresiba Treatment Helps to Control Blood Sugar Level (NCT06153537) | Novo Nordisk A/S | 2023-11-29 |
| A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight (NCT06131437) | Novo Nordisk A/S | 2023-11-27 |
| Levels of Inflammation in People With Cardiovascular Disease (POSEIDON) (NCT06122961) | Novo Nordisk A/S | 2023-11-23 |
| A First Human Dose Study Investigating Safety and Concentration of Study Medicine in the Blood Following Once Daily Oral Dosing of NNC0560-0004 in Healthy Adults. (NCT06133270) | Novo Nordisk A/S | 2023-11-13 |
| Patient Preference Study in Type-2 Diabetes Mellitus: Discrete Choice Experiment (DCE) to Support Novo Nordisk's Long-Acting Insulin (NCT06592950) | Novo Nordisk A/S | 2023-11-02 |
| Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-6856 in Healthy Participants, Including a Subset of Healthy Japanese Participants (NCT06069895) | Novo Nordisk A/S | 2023-10-04 |
| Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed (NCT06109935) | Novo Nordisk A/S | 2023-10-04 |
| A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III (NCT06097390) | Novo Nordisk A/S | 2023-09-28 |
| A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (NCT06065540) | Novo Nordisk A/S | 2023-09-27 |
| A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes (NCT05813912) | Novo Nordisk A/S | 2023-09-22 |
| A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin (NCT06064006) | Novo Nordisk A/S | 2023-09-15 |
| A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range (NCT06041217) | Novo Nordisk A/S | 2023-09-15 |
| A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity (NCT06049329) | Novo Nordisk A/S | 2023-09-14 |
| SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial (NCT04972721) | Novo Nordisk A/S | 2023-09-01 |
| A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight (NCT05996848) | Novo Nordisk A/S | 2023-08-15 |
| A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants (NCT05996874) | Novo Nordisk A/S | 2023-08-12 |
| Assessing Health-Related Quality of Life and Willingness to Pay for Weight Management in Asia-Pacific by Gender (NCT06260696) | Novo Nordisk A/S | 2023-08-10 |